Literature DB >> 20643135

Resident cardiac progenitor cells: at the heart of regeneration.

Sveva Bollini1, Nicola Smart, Paul R Riley.   

Abstract

Stem cell therapy has recently emerged as an innovative strategy over conventional cardiovascular treatments to restore cardiac function in patients affected by ischemic heart disease. Various stem cell populations have been tested and their potential for cardiac repair has been analyzed. Embryonic stem cells retain the greatest differentiation potential, but concerns persist with regard to their immunogenic and teratogenic effects. Although adult somatic stem cells are not tumourigenic and easier to use in an autologous setting, they exist in small numbers and possess reduced differentiation potential. Traditionally the heart was considered to be a post-mitotic organ; however, this dogma has recently been challenged with the identification of a reservoir of resident stem cells, defined as cardiac progenitor cells (CPCs). These endogenous progenitors may represent the best candidates for cardiovascular cell therapy, as they are tissue-specific, often pre-committed to a cardiac fate, and display a greater propensity to differentiate towards cardiovascular lineages. This review will focus on current research into the biology of CPCs and their regenerative potential. This article is part of a special issue entitled, "Cardiovascular Stem Cells Revisited".
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20643135     DOI: 10.1016/j.yjmcc.2010.07.006

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  57 in total

Review 1.  Embryonic stem cells for severe heart failure: why and how?

Authors:  Philippe Menasché
Journal:  J Cardiovasc Transl Res       Date:  2012-03-13       Impact factor: 4.132

Review 2.  Harnessing the potential of adult cardiac stem cells: lessons from haematopoiesis, the embryo and the niche.

Authors:  Gemma M Balmer; Paul R Riley
Journal:  J Cardiovasc Transl Res       Date:  2012-06-15       Impact factor: 4.132

3.  Localization of Islet-1-positive cells in the healthy and infarcted adult murine heart.

Authors:  Florian Weinberger; Dennis Mehrkens; Felix W Friedrich; Mandy Stubbendorff; Xiaoqin Hua; Jana Christina Müller; Sonja Schrepfer; Sylvia M Evans; Lucie Carrier; Thomas Eschenhagen
Journal:  Circ Res       Date:  2012-03-15       Impact factor: 17.367

Review 4.  Embryonic template-based generation and purification of pluripotent stem cell-derived cardiomyocytes for heart repair.

Authors:  Pieterjan Dierickx; Pieter A Doevendans; Niels Geijsen; Linda W van Laake
Journal:  J Cardiovasc Transl Res       Date:  2012-07-18       Impact factor: 4.132

5.  Differentiation induction of mouse cardiac stem cells into sinus node-like cells by co-culturing with sinus node.

Authors:  Yi-Bing Fang; Xuan Liu; Jing Wen; Xiao-Jun Tang; Feng-Xu Yu; Ming-Bin Deng; Chang-Xue Wu; Bin Liao
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 6.  Chasing c-Kit through the heart: Taking a broader view.

Authors:  Natalie A Gude; Mark A Sussman
Journal:  Pharmacol Res       Date:  2017-06-13       Impact factor: 7.658

Review 7.  The present and future role of ultrasound targeted microbubble destruction in preclinical studies of cardiac gene therapy.

Authors:  Lijun Qian; Barsha Thapa; Jian Hong; Yanmei Zhang; Menglin Zhu; Ming Chu; Jing Yao; Di Xu
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

8.  Bioengineering the infarcted heart by applying bio-inspired materials.

Authors:  Emil Ruvinov; Tamar Harel-Adar; Smadar Cohen
Journal:  J Cardiovasc Transl Res       Date:  2011-06-08       Impact factor: 4.132

Review 9.  The cardiac hypoxic niche: emerging role of hypoxic microenvironment in cardiac progenitors.

Authors:  Wataru Kimura; Hesham A Sadek
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 10.  Myocardial regeneration of the failing heart.

Authors:  Alexander T Akhmedov; José Marín-García
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.